Abstract
The ability to predict the conditions under which antibodies protect against viral infection would transform our approach to vaccine development. A more complete understanding is needed of antibody protection against lentivirus infection, as well as the role of mutation in resistance to an antibody vaccine. Recently, an example of antibody-mediated vaccine protection has been shown via passive transfer of neutralizing antibodies before equine infectious anemia virus (EIAV) infection of horses with severe combined immunodeficiency (SCID). Viral dynamic modeling of antibody protection from EIAV infection in SCID horses may lead to insights into the mechanisms of control of infection by antibody vaccination. In this work, such a model is constructed in conjunction with data from EIAV infection of SCID horses to gain insights into multiple strain competition in the presence of antibody control. Conditions are determined under which wild-type infection is eradicated with the antibody vaccine. In addition, a three-strain competition model is considered in which a second mutant strain may coexist with the first mutant strain. The conditions that permit viral escape by the mutant strains are determined, as are the effects of variation in the model parameters. This work extends the current understanding of competition and antibody control in lentiviral infection, which may provide insights into the development of vaccines that stimulate the immune system to control infection effectively.
Highlights
Despite advances in our understanding of the control of viral infection, a vaccine is still needed to best control human immunodeficiency virus type 1 (HIV-1) and other viruses that result in chronic infections
It is valuable for research focused on the development of protective vaccines against Equine infectious anemia virus (EIAV) and related lentiviruses, including HIV-1 [8,9]
The current study aims to understand the role that neutralizing antibody vaccines can play in the control of lentivirus infection
Summary
Despite advances in our understanding of the control of viral infection, a vaccine is still needed to best control human immunodeficiency virus type 1 (HIV-1) and other viruses that result in chronic infections.Knowledge of how antibodies can block the establishment of initial infection would transform our approach to vaccine development. Despite advances in our understanding of the control of viral infection, a vaccine is still needed to best control human immunodeficiency virus type 1 (HIV-1) and other viruses that result in chronic infections. Equine infectious anemia virus (EIAV) is a macrophage-tropic lentivirus that establishes a chronic, persistent viral infection in horses and ponies [3,4]. EIAV infection is used as an experimental system for the study of the immune control of persistent infection [7]. As such, it is valuable for research focused on the development of protective vaccines against EIAV and related lentiviruses, including HIV-1 [8,9]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.